Treatment of Generalized Myasthenia Gravis with Anti-Acetylcholine Receptor Antibodies (AChR-Ab+)
This protocol covers the management of generalized myasthenia gravis in patients with confirmed antibodies to acetylcholine receptors (AChR-Ab+) — a clinically distinct subgroup for which a specific evidence-based treatment pathway applies.
Generalized myasthenia gravis with positive anti-acetylcholine receptor antibodies (AChR-Ab+). This antibody status defines the patient population and is central to the therapeutic strategy.
An adequate trial of immunotherapy forms part of the approach in this setting. For select nonthymomatous patients, surgical intervention may also be considered early in the disease course. The full eligibility criteria, sequencing, and treatment options are available in the complete protocol.
The primary measure of treatment success is a meaningful reduction in the quantitative MG (QMG) score, reflecting objective improvement in neuromuscular status.
References
DOI: 10.1212/WNL.0000000000011124
- In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations.
- Thymectomy for MG is an elective procedure and should be performed when the patient is stable and deemed safe to undergo a procedure where postoperative pain and mechanical factors can limit respiratory function.
- An effect favoring thymectomy was seen in both of the coprimary outcome measures: reductions in the time-weighted average quantitative MG (QMG) score and the time-weighted average alternate-day prednisone dose.